article thumbnail

The Cannabis Cancer Connection

Project CBD

United Kingdom-based GW Pharmaceuticals has produced the world’s first approved cannabis-based medicines for the UK, US, and European markets, Sativex® and Epidiolex®. GW Pharmaceuticals’ research on glioblastoma multiforme (GBM) is important and promising. Note: In May 2021, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals.]

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What's at Stake in the 2024 Election?

Americans for Safe Access

territories, often serving as a crucial alternative when conventional treatments have failed or as a safer option compared to pharmaceuticals. Today, cannabis-based therapies provide relief to over 6 million Americans registered in medical cannabis programs in 38 states, D.C., and four of the five U.S.

Therapy 212
article thumbnail

This app-guided psychedelic treatment works when antidepressants don’t

The Cannigma

When antidepressants were first introduced in the mid-20 th century, they were a breakthrough in pharmaceuticals. Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment?

Treatment 140
article thumbnail

Cannabinoids for Scleroderma

Project CBD

Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2. Referred to as a “selective CB2 agonist ,” such a compound would appear to have potential as a treatment for scleroderma.

article thumbnail

Prohibition Publish 2nd Ed Of The Pharmaceutical Cannabis Report

Cannabis Law Report

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. In Europe, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products.

article thumbnail

Is Cannabis a Viable Mental Health Treatment Option? Part 1 of 3

Kind Meds (Cannabis Education Blog)

One of the biggest areas of contention in the public debate about cannabis legalization is the viability of medicinal cannabis as a treatment for many mental health disorders, such as anxiety, depression, bipolar disorder, schizophrenia, and others. Cannabis Is a Unique Substance and Treatment Method. CBD for Mental Health Treatment.

Treatment 122